Aurobindo Pharma Limited has announced the incorporation of a new wholly owned step-down subsidiary, Arrow Pharma Production SAS, in France. Established on May 21, 2026, the new entity will focus on expanding the manufacturing of generic formulations. The subsidiary was created with a capital investment of 100,000 EUR, fully subscribed in cash, and will operate under the company’s existing indirect subsidiary, Agile Pharma BV.
Strategic Expansion in Europe
Aurobindo Pharma has strengthened its European manufacturing footprint through the establishment of Arrow Pharma Production SAS in France. The company was officially incorporated on May 21, 2026. This development aligns with the company’s long-term strategy to bolster its generic drug manufacturing capabilities and improve its direct presence within the European pharmaceutical market.
Details of the New Subsidiary
The new entity, Arrow Pharma Production SAS, is held by Agile Pharma BV, the Netherlands, which is a wholly owned step-down subsidiary of Aurobindo Pharma. Consequently, the new French entity is now a wholly owned step-down subsidiary of the listed company.
Investment and Capital Structure
The incorporation involved a cash subscription to the share capital of 100,000 EUR. The share structure consists of 100,000 shares, each with a nominal value of 1 EUR. The project is specifically designed to facilitate the growth of generic formulation manufacturing, allowing the company to leverage local production capacity in France to better serve its markets.
Source: BSE
